



www.genfit.com

GENFIT INITIATES THE USE OF ITS FINANCIAL AGREEMENT WITH YORKVILLE

The Company achieves a first capital increase of €200K as part of its equity financing agreement with Yorkville, that could reach €5.3M over 2 years

Lille (France), Cambridge (Massachusetts, United States), October 6, 2011 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces a private placement of €199,998.54 to YA Global Master SPV Ltd, a fund managed by Yorkville Advisors LLC.

As announced in the Company's press release of August 24, 2011, this first capital increase operation follows the delegations granted to the Management Board by the fifth and sixth resolutions adopted by the Extraordinary General Meeting held on September 28, 2011.

This capital increase was generated by the issuance of 84,033 new Company shares, at a price of €2.38 per share. The settlement/delivery of these shares is due to take place on October 7, 2011.

This placement, like the remaining funds that could be activated as part of the Company's financial agreement with Yorkville, will contribute to an increase in the Company's available financial resources. Funds will allow GENFIT to continue or share the development of its leading drug candidate, GFT505, up to the end of Phase II clinical trials at the latest, and to maximize its value before the transfer of its commercialization rights to a pharmaceutical company.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000

MILESTONES – Press Relations

Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – barabian@milestones.fr